.
.
.
.
Coronavirus

US FDA grants Pfizer COVID-19 vaccine full approval

Published: Updated:

The US Food and Drug Administration on Monday fully approved Pfizer’s COVID-19 vaccine, a move expected to trigger a new wave of vaccine mandates as the delta variant batters the country.

For more coronavirus news, visit our dedicated page.

“The FDA’s approval of this vaccine is a milestone as we continue to battle the COVID-19 pandemic,” acting FDA Commissioner Janet Woodcock said in a statement.

“While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated.”

The COVID-19 vaccine, which may now be marketed under its brand name Comirnaty, is the first to receive full approval.

Tens of millions of shots have already been administered under an emergency use authorization (EUA) that was granted on December 11, 2020.

The decision to award it approval was based on updated data from the drug’s clinical trial, including a longer duration of follow-up, with safety and effectiveness evaluated among more than 40,000 people.

The US military has previously announced it will mandate the vaccine as soon as it receives full approval, and a slew of private businesses and universities are expected to follow.

The vaccine remains available under emergency use authorization to children aged 12 to 15, but because it has now been fully approved, physicians may prescribe it to children under 12 if they believe it will be beneficial.

Read more:

US FDA aims to give full approval to Pfizer COVID-19 vaccine on Monday: NYT

US health officials call for booster shots to all Americans against COVID-19

US pharmacist arrested for selling dozens of COVID-19 vaccine cards on eBay